Trial Profile
A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenoid cystic carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 01 Dec 2023 Results assessing effect of Nivolumab plus ipilimumab in advanced salivary gland cancerpublished in the Nature Medicine
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2025.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2025.